Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-PCS, an RNAi therapeutic for the treatment of severe hypercholesterolemia.

11 Jul 2011

Merck Serono announces recipients of second Grant for Fertility Innovation

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announces the recipients of its second Grant for Fertility Innovation.

8 Jul 2011

Allegro completes $5.4M Series A extension financing

Allegro Diagnostics today announced that it has closed a $5.4M Series A extension financing. The company's existing venture investors, Kodiak Venture Partners and Catalyst Health Ventures, participated in the round.

8 Jul 2011

Understanding glioblastoma at the genetic, molecular level

Glioblastoma is the most common and most lethal form of brain tumor in people. Research published in the International Journal of Computational Biology and Drug Design offers a novel way to determine what biological functions go awry when the tumor first begins to form.

7 Jul 2011

Patients with high EGFR expression more likely to benefit from cetuximab plus chemotherapy

High epidermal growth factor receptor expression was a good predictor of which lung cancer patients would survive longer when cetuximab was added to first-line chemotherapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

5 Jul 2011

NovaUCD honors leading cancer researcher with 2011 Innovation Award

Professor William Gallagher, a leading cancer biology researcher in UCD's School of Biomolecular and Biomedical Science, was today presented with the NovaUCD 2011 Innovation Award.

5 Jul 2011

Amyloid peptide Aβ43 may serve as biomarker for diagnosis of Alzheimer's

Researchers at the RIKEN Brain Science Institute (BSI) and their collaborators have shed light on the function of a little-studied amyloid peptide in promoting Alzheimer's disease.

4 Jul 2011

Simple blood test for melanoma-inhibitory activity could detect neurofibromas

Neurofibromatosis (NF1) is a genetic condition which affects one in every 3,000 people. The severity of symptoms can range from benign 'café au lait' patches on the skin, through small tumors under the skin and deep plexiform neurofibromas, to malignant tumors of the nerve sheath.

4 Jul 2011

Six new scientists to receive SWCRF grants for cancer research

This year, the Samuel Waxman Cancer Research Foundation awarded individual grants to six new researchers in addition to funding 18 collaborative grants and three ongoing individual grants. The Foundation expanded its scientific grants program to a total of more than $3.1 million.

1 Jul 2011

Boston University, University of Utah Foundation and Allegro enter license agreement for molecular testing platform

Allegro Diagnostics today announced that the company has entered into an exclusive license agreement with Boston University and the University of Utah Foundation for intellectual property related to the company's molecular testing platform. This platform utilizes gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer.

30 Jun 2011

DiagnoCure, Signal Genetics enter commercialization collaboration for Previstage GCC Colorectal Cancer Staging Test

Signal Genetics, a privately held predictive genetic testing company focusing on oncology, and DiagnoCure, Inc., a life sciences company that develops and commercializes high-value cancer diagnostic tests, today announced a collaboration arrangement valued at US$13.3M over the first five years.

29 Jun 2011

Amorfix fiscal 2011 net loss decreases to $3,330,437

Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the year ended March 31, 2011, as well as financial results for the fourth quarter.

29 Jun 2011

Mount Sinai gene therapy improves cardiac function in people with severe heart failure

Researchers at Mount Sinai School of Medicine have found in a Phase II trial that a gene therapy developed at Mount Sinai stabilized or improved cardiac function in people with severe heart failure. Patients receiving a high dose of the therapy, called SERCA2a, experienced substantial clinical benefit and significantly reduced cardiovascular hospitalizations, addressing a critical unmet need in this population.

29 Jun 2011

Scientists discover how bacteria invade heart tissue and cause endocarditis

Scientists have discovered the tool that bacteria normally found in our mouths use to invade heart tissue, causing a dangerous and sometimes lethal infection of the heart known as endocarditis.

28 Jun 2011

Researchers demonstrate how Runx3 protein could suppress breast cancer tumor growth

Researchers have identified a protein long known to regulate gene expression as a potent suppressor of breast cancer growth. Their study, in the journal Oncogene, is the first to demonstrate how this protein, known as Runx3, accomplishes this feat.

27 Jun 2011

Enrollment complete in ERYTECH Pharma's Graspa Phase I clinical trial for pancreatic cancer

ERYTECH Pharma has just completed the enrollment of patients in a Phase I clinical trial with its flagship product for pancreatic cancer, Graspa®. This product contains the enzyme L-asparaginase encapsulated in red blood cells, using technology owned by ERYTECH Pharma.

27 Jun 2011

Short-term lowering of PreDx DRS may reduce risk of developing diabetes

Data presented today from an analysis of samples from the European Diabetes Prevention Study (EDIPS) showed that the PreDx Diabetes Risk Score (DRS) is lowered by lifestyle intervention, which correlates to a reduction in the risk that patients will develop diabetes over time.

27 Jun 2011

New automated sample preparation system developed for proteomic biomarker discovery and validation

A new automated sample preparation system based on Tecan's Freedom EVO- 200 liquid handling platform has been developed for proteomic biomarker discovery and validation in collaboration with the Translational Genomics Research Institute (TGen) and the Biodesign Institute at Arizona State University.

24 Jun 2011

New sAPPβ biomarker may identify people at risk of developing Alzheimer's

A new biomarker may help identify which people with mild memory deficits will go on to develop Alzheimer's disease, according to a new study published in the June 22, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

23 Jun 2011

Integromics announces winners of proteomics grant competition

Integromics, a leader in IT solutions for life sciences in the field of genomics and proteomics, today announces the two winners of the Integromics 'Proteomics Mass Spectrometry Research Grant' competition, for the creative use of Integromics' OmicsHub(R) proteomics solution. The winners are Prof. Stephen Pennington from University College Dublin and Dr. Michelle Cilia from the USDA-ARS (U.S. Department of Agriculture - Agricultural Research Service).

22 Jun 2011

Biomarker News and Research

Further Reading

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Merck Serono announces recipients of second Grant for Fertility Innovation

Allegro completes $5.4M Series A extension financing

Understanding glioblastoma at the genetic, molecular level

Patients with high EGFR expression more likely to benefit from cetuximab plus chemotherapy

NovaUCD honors leading cancer researcher with 2011 Innovation Award

Amyloid peptide Aβ43 may serve as biomarker for diagnosis of Alzheimer's

Simple blood test for melanoma-inhibitory activity could detect neurofibromas

Six new scientists to receive SWCRF grants for cancer research

Boston University, University of Utah Foundation and Allegro enter license agreement for molecular testing platform

DiagnoCure, Signal Genetics enter commercialization collaboration for Previstage GCC Colorectal Cancer Staging Test

Amorfix fiscal 2011 net loss decreases to $3,330,437

Mount Sinai gene therapy improves cardiac function in people with severe heart failure

Scientists discover how bacteria invade heart tissue and cause endocarditis

Researchers demonstrate how Runx3 protein could suppress breast cancer tumor growth

Enrollment complete in ERYTECH Pharma's Graspa Phase I clinical trial for pancreatic cancer

Short-term lowering of PreDx DRS may reduce risk of developing diabetes

New automated sample preparation system developed for proteomic biomarker discovery and validation

New sAPPβ biomarker may identify people at risk of developing Alzheimer's

Integromics announces winners of proteomics grant competition

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News